Submission declined on 14 September 2024 by Johannes Maximilian (talk). This submission does not appear to be written in the formal tone expected of an encyclopedia article. Entries should be written from a neutral point of view, and should refer to a range of independent, reliable, published sources. Please rewrite your submission in a more encyclopedic format. Please make sure to avoid peacock terms that promote the subject.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Once you save your changes using the "Publish changes" button below, you will be able to resubmit your draft for review by pressing the "Resubmit" button that will appear here. |
Peixuan Guo | |
---|---|
郭培宣 | |
Born | China |
Alma mater | University of Minnesota |
Scientific career | |
Fields | Virology, RNA Nanotechnology, Nanopore Technology |
Institutions | Purdue University, University of Cincinnati, University of Kentucky, Ohio State University |
Doctoral advisor | Enzo Paoletti and Bernard Moss |
Website | https://rnanano.osu.edu/Guo/peixuanguo.html |
Peixuan Guo is a Chinese-American virologist and nanotechnologist. He is the Sylvan G. Frank Endowed Chair in Pharmaceutics and Drug Delivery[1] and the director of the Center for RNA Nanobiotechnology and Nanomedicine at The Ohio State University.[2] He is also a Fellow of the National Academy of Inventors.
Guo is known for proposing the idea that a large number of previously undiscovered small RNA exist in cells called sRNA (Guo P et al. A small viral RNA is required for in vitro packaging of bacteriophage phi29 DNA. Science 1987; 236: 690)[3]; constructed 1st viral DNA packaging motor (PNAS 1986); discovered phi29 motor pRNA (Science, 1987); proved the concept of RNA nanotechnology (Mol Cell 1998, featured in Cell[4],1998; 4 papers in Nat Nanotechnol[5] 2009, 2010, 2011, 2018; Nature Comm, 2019); he invented a novel method for the production of the vaccinia virus mRNA capping enzyme (PNAS, 1990 ,7:4023) that are used currently as an essential component for the production of COVID-19 mRNA vaccine; his team invented a patented method for the production of COVID-19 mRNA vaccine, invented a method for the use of TIRF System to count single-fluorophores molecules (EMBOJ, 2007); invented a unique method for single pore sensing by incorporating phi29 motor channel into the membrane (Nat Nanotechnol, 2009); discovered a 3rd class of biomotor using revolving mechanism without rotation; discovered that RNA is like rubber and amoeba with unusually high efficiency for passive tumor targeting and regression with quick kidney clearance, thus undetectable toxicity. He invented the methods to use RNA nanotechnology to make the insoluble and toxic cancer drugs soluble and nontoxic and invented RNA nanotechnology to decorate exosomes with a ligand for cancer targeting using the directionality of antibody-like (i.e., Y-shaped) RNA arrowtail (Nat Nanotechnol, 2017). He also invented method for the delivery of RNAi to the cytosol of cancer cells without endosome trapping; his team invented Exojuice for exosome purification with a simple one step 2 by combination of zonal and density gradient. All these invention has enable his team to achieve the treatment of liver cancer, lung cancer, brain cancer, colorectal cancer, breast cancer; stomach cancer, and prostate cancer in preclinical trials. ExonanoRNA LLC, whom Guo is the founder of, is actively working toward clinical trials for the treatment of these cancers.
Guo has 70 Patents filed, 16 patents granted, and 54 are in provisional and PCT; most of them are in RNA nanotechnology and therapeutics, and RNA-ligand displayed exosomes for the delivery of RNAi.